Abstract

The Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) pandemic represents a global challenge. SARS-CoV-2's ability to replicate in host cells relies on the action of its non-structural proteins, like its main protease (Mpro). This cysteine protease acts by processing the viruses' precursor polyproteins. As proteases, together with polymerases, are main targets of antiviral drug design, we here have performed biochemical high throughput screening (HTS) with recombinantly expressed SARS-CoV-2 Mpro. A fluorescent assay was used to identify inhibitors in a compound library containing known drugs, bioactive molecules and natural products. These screens led to the identification of 13 inhibitors with IC50 values ranging from 0.2 μM to 23 μM. The screens confirmed several known SARS-CoV Mpro inhibitors as inhibitors of SARS-CoV-2 Mpro, such as the organo-mercuric compounds thimerosal and phenylmercuric acetate. Benzophenone derivatives could also be identified among the most potent screening hits. Additionally, Evans blue, a sulfonic acid-containing dye, could be identified as an Mpro inhibitor. The obtained compounds could be of interest as lead compounds for the development of future SARS-CoV-2 drugs.

Highlights

  • The agent behind the Coronavirus Disease 2019 (COVID-19) pandemic, SARS-CoV-2, is an RNA virus from the betacoronavirus genus [1, 2]

  • As viral proteases, following polymerases, are the most prominent targets for antiviral drug design [9], here we describe initial biochemical screenings with recombinant purified SARS-CoV-2 main protease (Mpro) performed in order to define possible candidates which could serve as lead compounds for the design of future COVID-19 therapies

  • In order to contribute to the ongoing worldwide research and development efforts to contain COVID-19, we cloned, expressed recombinantly in E.coli BL21(DE3) and purified an important drug target of SARS-CoV-2, its main protease (Mpro)

Read more

Summary

Introduction

The agent behind the Coronavirus Disease 2019 (COVID-19) pandemic, SARS-CoV-2, is an RNA virus from the betacoronavirus genus [1, 2]. As viral proteases, following polymerases, are the most prominent targets for antiviral drug design [9], here we describe initial biochemical screenings with recombinant purified SARS-CoV-2 Mpro performed in order to define possible candidates which could serve as lead compounds for the design of future COVID-19 therapies.

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.